Date post: | 18-Apr-2015 |
Category: |
Documents |
Upload: | hagit-givati |
View: | 67 times |
Download: | 3 times |
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
CLINICAL STUDIES PROCEDURE
Approvals:
Name Title Signature Date
Author
Reviewed by
Approved by
Change control:
Rev. Description of change Approved by DCN Signature Date
01
02
03
QP-02-08 Page 1 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
1. Objective
To define the activities related with the performance of Clinical Studies by [company].
2. General
2.1. Clinical studies are conducted by [company] as part of the validation activities.
2.2. This procedure applies to all clinical studies, sponsored by [company].
2.3. The purpose of this document is to ensure that clinical investigations are properly
monitored and documented, and meet international regulatory requirements (section 4
Reference Documents).
3. Applicable Documents
Requirements stated in the following documents apply as appropriate to the context:
3.1. Procedure QP 00-02 - Quality Manual.
3.2. Procedure QP 00-03 - Terms & Definitions.
3.3. Procedure QP 01-01 - Quality Policy.
3.4. Procedure QP 02-01 - Design and Development Planning.
3.5. Procedure QP 02-02 - Project Planning and Management.
3.6. Procedure QP-03-03-01 Controlled document types & control
3.7. Procedure QP 12-01 - Record Types and Retention.
3.8. [company] clinical study forms (QF-02-08)
4. Reference Documents
Information contained in the following documents is relevant as appropriate to the context.
4.1. 21 CFR Part 820 – Quality System Regulation.
4.2. ISO 13485– Medical Devices – Quality Management System – Requirements for
regulatory purposes
4.3. Directive 93/42/EEC for medical devices
4.4. EN ISO 14155-1, Clinical investigation of medical devices for human subjects – Part 1:
General requirements.
4.5. Guidance for Good Clinical Practice, ICH Harmonized Tripartite guideline, 1996
4.6. Helsinki declaration
QP-02-08 Page 2 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
4.7. FDA publication “Perspectives on Clinical Studies for Medical Device Submissions
(Statistical).”
4.8. FDA publication “Guidance for Industry: Computerized Systems Used in Clinical Trials.”
4.9. FDA publication “A Regulatory Perspective for Bayesian Clinical Trials.”
5. Definitions and abbreviations
5.1. Documents
5.1.1. Case Report Form (CRF) – A printed, optical, or electronic document designed to
record all of the protocol’s required information to be reported to the sponsor on each
trial subject.
5.1.2. Essential documents – Documents which individually and collectively permit
evaluation of the conduct of a study and the quality of the data produced that are to be
held in the ‘regulatory binder” kept at the study site and at sponsor’s headquarters. (See
detailed list of primary essential documents for the conduct of a clinical study in ref. 6.4
and appendix 5).
5.1.3. Informed Consent Form (ICF) –A process by which a subject voluntarily confirms
his or her willingness to participate in a particular trial, after having been informed of
all aspects of the trial that are relevant to the subject’s decision to participate. Informed
consent is documented by means of a written, signed and dated informed consent form
(ICF).
5.1.4. Investigator Brochure (IB) – A compilation of the clinical and non-clinical data on the
investigational product(s) which is relevant to the study of the investigational product(s)
in human subjects.
5.1.5. Protocol (CIP- Clinical Investigational Plan) – A document that describes the
objective(s), design, methodology, statistical considerations, and organization of a trial.
The protocol usually also gives the background and rationale for the trial, but these
could be provided in other protocol referenced documents.
5.1.6. Protocol Amendment – A written description of a change(s) to or formal clarification
of a protocol.
QP-02-08 Page 3 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
5.2. Personnel
5.2.1. Principal Investigator (PI) – A person responsible for the conduct of the clinical trial
at the trial sites. The PI is responsible for ensuring that the investigation is conducted
according to the signed clinical study agreement, the investigational plan, and
applicable regulations; for protecting the rights, safety, and welfare of subjects under
the investigator's care; and for the control of device under investigation. If a trial is
conducted by a team of individuals at a trial site the PI is the responsible leader of the
team.
5.2.2. Investigator – A person responsible for the conduct of the clinical trial at the trial site.
5.2.3. Monitor or Clinical Research Associate (CRA) - A person, appointed by the sponsor,
whose responsibility it is to oversee the progress of a clinical trial, and ensure that it is
conducted, recorded, and reported in accordance with the protocol, Standard Operating
Procedures (SOP), Good Clinical Practice (GCP) principles and the applicable
regulatory requirements.
5.2.4. Sponsor – An individual, company, institution, or organization which takes
responsibility for the initiation, management, and/or financing of a clinical trial.
5.2.5. Contract Research Organization (CRO) - A person or an organization (commercial,
academic or other) contracted by the sponsor to perform one or more of a sponsor’s
trial-related duties and functions.
5.2.6. Study coordinator - a person at the study site that works together with the sponsor
representatives to assure that the data collection and the study execution is performed
according to GCP, site SOPs and sponsor’s SOPs.
5.2.7. Institutional Review Board / Ethics Committee (IRB / EC) – An independent body
constituted of medical/scientific/non-scientific members, whose responsibility it is to
ensure the protection of the rights, safety and well-being of human subjects involved in
a trial by, among other things, reviewing, approving and providing continuing review of
trial protocol and amendments and of the methods and material to be used in obtaining
and documenting informed consent of the trial subjects.
QP-02-08 Page 4 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
5.3. Other
5.3.1. Adverse Event (AE) - Any undesirable experience occurring to a subject during a
clinical study, whether or not considered related to the investigational product.
5.3.2. Serious Adverse Event (SAE) - means an adverse experience that is fatal, life-
threatening, or which results in hospitalization or prolongation of hospitalization.
5.3.3. Audit – A systematic and independent examination of trial related activities and
documents to determine whether the evaluated trial related activities were conducted,
and the data were recorded, analyzed and accurately reported according to the protocol,
sponsor’s standard operating procedures (SOP’s), Good Clinical Practice (GCP), and
the applicable regulatory requirements.
5.3.4. Good Clinical Practice (GCP) – A standard for the design, conduct, performance,
monitoring, auditing, recording, analyses and reporting of clinical trials that provides
assurance that the data and reported results are credible and accurate, and that the rights,
integrity, and confidentiality of trial subjects are protected.
6. Application
6.1. Confidentiality
All patient records shall be maintained confidential and information released shall conceal the
identity of individual patients except where the identity must be disclosed legally or is
otherwise necessary. Confidentiality policy will be explained to the patient in the ICF.
6.2. Documentation
Unless otherwise stated, all original copies of [company] forms to be filled-in and signed
during the study, and the informed consent form, should be kept at the site regulatory binder. A
copy of the signed forms should be kept at the sponsor’s headquarters.
This does not apply to the completed CRF.
6.3. Study Initiation
6.3.1. Study Design
Clinical investigations shall be designed to yield scientifically valid results. Statistical
considerations shall be taken into account in designing the study, in particular for
QP-02-08 Page 5 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
determining the number of patients required. In case of feasibility or FIM (First In Man)
studies statistical considerations or analysis may not be required.
6.3.2. Selection of Investigators
The Clinical Affairs Manager shall assess and document in writing the approval of the
inclusion of each investigator by the PI. The following criteria are examples for this
assessment:
The investigator has appropriate qualifications and experience to carry out the
clinical study and is able to undertake all the activities specified in the protocol.
The investigator understands his/her responsibilities for ensuring that the study is
conducted in accordance with the protocol and GCP, and that accurate results are
recorded and reported within the agreed timetable.
The investigator has sufficient interest and time to participate in the study.
The anticipated recruitment rate at the investigator’s site meets the study objectives.
The investigator’s site has access to adequate staffing, facilities, and equipment for
the proper conduct of the study.
The investigator agrees to provide his/her CV
The Principal Investigator signs the Clinical Study Agreement.
The investigator is obligated to allocate proper conditions for monitoring and to
cooperate with the monitor.
6.3.3. Regulatory Aspects
The clinical affairs manager will obtain confirmation that all clinical sites are in
conformity with laws and regulations of the country in which the site is located, in
addition to the documents specified in section 4. This is usually part of the clinical
study agreement.
6.3.4. Protocol and Case Report Forms (CRF)
6.3.4.1. A clinical study protocol and a set of CRF’s shall be prepared and approved
prior to the initiation of the study. Medically qualified input is required during
the drafting of the protocol and CRF's. A recommended protocol’s table of
contents is shown in Appendix 1.
QP-02-08 Page 6 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
6.3.4.2. Once the protocol is signed and approved by the IRB/EC any alteration to
the protocol is documented as ‘amendments’, which should be agreed upon and
signed by the PI and the Clinical Affairs Manager and implemented via
[company] QP-03-03-01 Controlled document types & control. If the change is
significant, the amendment should be submitted to the Ethics Committee who
originally approved the study for re-approval. Minor changes in the study
protocol should be delivered to the EC via a protocol notification form at the
next formal contact with the EC, or according to the EC SOPs, as appropriate.
6.3.4.3. Amendments to the protocol are valid in all clinical sites except for cases in
which it is clearly written that the amendment will be activated in specific
clinical sites.
6.3.4.4. The cover page of the protocol includes the investigator’s signature/s. An
additional first page with a change control table and an identification table will
be kept at [company], attached to the original document. Protocols and CRF’s
are assigned with an internal separate document number per [company]’s
document control procedure.
6.3.4.5. Changes are documented as ‘amendments’, [company] QP-03-03-01
Controlled document types & control. In addition, amendments are signed by
the Clinical Affairs Manager, the PI and if required by the EC. The filled-in
forms are kept in the regulatory binder at the site and at the sponsor’s
headquarters.
6.3.5. Investigator’s Brochure
An Investigator’s Brochure summarizing all relevant data on the investigational
product, including: pre-clinical, clinical (if applicable), and safety data, shall be
prepared and provided to each investigator participating in the study. See Appendix 2
for a list of contents.
6.3.6. Informed Consent
Patients enrolled to the clinical study or, where appropriate, their legal representative,
shall be provided both verbally and in writing with information on the investigational
product and procedures. Their consent to be included in the study shall be expressed by
the fact that they have written their name, signed and dated the consent form, prior to
QP-02-08 Page 7 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
the enrollment in the study. A copy of the signed form will be given to each subject.
The informed consent form is considered a controlled document - complete informed
consents forms will be kept as records at the study site/s file and in the patient medical
records, in addition to the copy provided to the patient. A significant change to its
content requires an EC approval (via a submission of an amendment). The principles of
the informed consent form content are detailed in Appendix 3.
ICF signing: the patient will write his/her name, sign and date the ICF. None of this
data will be completed by the physician.
Copies of ICF:
1. Original signed ICF is kept in the site file.
2. Copy of the signed ICF is provided to the patient
3. Additional copy of the signed ICF is kept in the patient medical records.
6.3.7. Indemnities / Insurance
Any indemnification required by investigators or ethics committees shall be arranged
prior to the initiation of the study, as well as the clinical trial insurance that is required
in relevant countries. The Clinical Affairs Manager shall ensure that either these have
been obtained or that [company] has authorized the CRO to obtain them on its behalf.
6.3.8. Agreements
6.3.8.1. Prior to study initiation, a written agreement shall be signed by the PI
indicating his/her willingness to adhere to the protocol, and defining any other
responsibilities or arrangements not covered by the protocol.
6.3.8.2. The PI and all investigators involved with the study should sign a financial
disclosure form, reporting any financial interest in the company or the test
product.
6.3.9. Ethics Committee
6.3.9.1. The study protocol and other relevant documentation, e.g., ICF, IFU, a
sample of CRF and Investigator’s Brochure, shall be submitted to the
appropriate Ethics Committee for review. Normally a separate application shall
be made for each participating center, unless there are arrangements to accept
Ethics Committee reviews carried out elsewhere.
QP-02-08 Page 8 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
6.3.9.2. No center may start the study until the appropriate Ethics Committee
approval has been obtained in writing. A copy of the written approval shall be
kept in the regulatory binder kept in the sponsor’s clinical department and in the
site file.
6.3.9.3. The documents to be included in the Ethics Committee submission are
detailed in Appendix 4. Additional documents may be required, according to the
specific EC/IRB SOPs.
6.3.9.4. Note: In countries in which additional requirements apply (e.g., notification
to- or approval from- the EC or Competent Authority, or approval by national
EC / hospital manager), the study may start only after all requirements are
fulfilled.
6.3.10. Supply of the Investigational device
6.3.10.1. Only approved product, sterile if applicable, after the completion of all
relevant manufacturing and quality tests, shall be used for clinical studies. It is
the quality assurance responsibility to verify the completion of the activities and
completeness of the documentation for traceability purposes.
6.3.10.2. All products supplied for clinical study use shall be labeled “For Clinical
Investigation only” and the package will include instructions for use (IFU), as
applicable.
6.3.10.3. Shipment and use of the product will be documented in the appropriate
[company] clinical forms and delivery notes. The filled-in forms and delivery
notes will be kept at the site file and at the sponsor file.
6.3.11. Training
Any clinical study of an investigational product will be initiated only after an
appropriate training has been given. The extent, nature and responsibility of the training
shall be decided by the clinical affairs manager and, as appropriate, by the medical
director and the monitor. In addition, GCP training will be provided to all site
personnel, and a specific training will be provided to the PI, reviewing PI obligations
and responsibilities.
QP-02-08 Page 9 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
6.4. Conduct of Study
6.4.1. Site initiation visit
6.4.1.1. Before any site(s) begin the study, a study initiation visit shall be carried out. The
site initiation visit may take place either at the specific study site or as a multi-site
meeting at a location decided upon by the sponsor. The investigator(s), study
coordinators, monitors and the sponsor’s representatives shall participate in the
visit.
6.4.1.2. The issues to be discussed during the site initiation visit include issues such as:
protocol design adherence, training of the use of the investigational product,
recruitment methods, study timelines, SAE reporting, data documentation (CRF),
informed consent procedure, monitoring and GCP adherence.
6.4.1.3. Site initiation visit shall be documented in a report (using [company] QF-02-08z
form). The report should detail all topics covered during the visit, including training
on specific procedures and decisions as to study specific requirements.
6.4.1.4. The report shall be filed at each study site and shell be kept at the sponsor’s
headquarters and at the site file.
6.4.2. Monitoring visits
6.4.2.1. Monitoring visits shall be conducted on a regular basis as defined by the sponsor.
6.4.2.2. The investigator and other staff members (optional) shall participate in the
meeting at the beginning of each visit.
6.4.2.3. Prior to each monitoring visit, the monitor should review previous reports /
communication, identify outstanding issues and be familiar with the status of the
site(s).
6.4.2.4. The visit shall start with a short update about the progress of the study and a
report of the pros and cons of the study proceeding.
6.4.2.5. Verification of clinical data: The monitor shall verify completeness, legibility,
clarity, obvious errors, and protocol compliance of signed inform consent forms,
CRF’s and essential documents to be held in the regulatory binder kept on site. All
reasonable attempts to clarify and complete these data shall be made with the
QP-02-08 Page 10 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
investigator. During monitoring visits, the CRF’s shall be checked against source
data (e.g., patient hospital files) to verify that the CRF’s accurately reflect the cases
in question.
6.4.2.6. Data collection: The monitor shall collect all CRF’s that have been completed.
6.4.2.7. Monitor report: After each monitoring visit, the monitor shall write a
monitoring report including site performance and study progress and problems. The
report should include corrective actions and steps for avoiding future violations. The
report shall be sent to the investigator. Each monitoring visit shall be documented in
the appropriate [company] monitoring log.
6.4.3. Adverse Events, nonconformities and customer complaints
6.4.3.1. Information concerning serious adverse events and product-related adverse
events shall be reported immediately (within 24 hours) to the sponsor. The event
may be reported by telephone but it should always be followed by a written and
signed report.
The Clinical Affairs Manager will ensure that:
Any regulatory requirements for reporting adverse events are met.
Any requirements to inform Ethics Committees of adverse events are met.
All the investigators participating in the study are notified.
Consideration is given to any necessary modifications to the study, including its
possible discontinuation, consequent to the reported adverse event.
6.4.3.2. Complaints that are outside the scope of adverse events (e.g., complaints on
device malfunction, lack of equipment, inadequate training) shall be reported to
[company] and handled by the Clinical affairs Manager. The event details shall be
documented in [company] form QF-02-08u-01. The event discussions, conclusion,
action suggested and taken shall be summarized on ‘CAPA form’.
6.4.3.3. Nonconformities that are found by [company] during the study are documented
using the ‘nonconforming product’ procedure [company] QP-09-01-01 (NCR) Non
Conforming Material Procedure.
6.4.4. Audits
6.4.4.1. Audit shall be independent of and separate from routine monitoring, and shall be
under the responsibility of the Quality Assurance department. The QA department
QP-02-08 Page 11 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
may conduct the audit or appoint an individual on its behalf to conduct the audit.
The QA department should ensure that the auditors are qualified by training and
experience to conduct audits properly.
6.4.4.2. Performance of audit is the sponsor decision.
6.4.4.3. The audit(s) shall, preferably, be conducted at a mid-point of the clinical trial.
6.4.4.4. The observations and findings of the auditor(s) should be documented in a final
audit report and shall be kept as a quality record at [company]. The report shall not
be part of the regulatory binder of the trial that will be submitted to the authorities.
6.5. Study Closure
6.5.1. Close out visit
6.5.1.1. The monitor or clinical affairs manager should ensure that all patient’s data are
documented and recorded (files and CRF copy on site).
6.5.1.2. The monitor or clinical affairs manager shall discuss with the investigator GCP
requirements for storage and archiving of study material, responsibility to inform
the EC of study termination and publication policy of study results and data.
6.5.1.3. Data collection: All remaining used and unused CRF’s will be collected.
6.5.1.4. A written site close out report will be written. The report shall give an overview
of the study conduct and results. The report, together with a follow-up letter shall be
sent to the investigator.
6.5.2. Product Allocation/Return
On completion of the study, the monitor(s) shall collect from the clinical centers all
remaining equipment and return them to [company].
6.5.3. Reporting
A report of the study, which incorporates data from each study site, shall be
prepared. The report shall include a description of the study design and
methodology, data analysis, statistical analysis (if appropriate), and a clinical
appraisal. The final report shall be signed by each clinical investigator, the clinical
affairs manager, and by the CRO representative (if any). (Note: Should any
investigator refuse to sign the final report, an explanation shall be provided.).
6.5.4. For a clinical study report template please see [company] QF-02-08ai-01. Archiving
QP-02-08 Page 12 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
All records relating to the study shall be stored in a secure place in [company] and
at the study site for the appropriate period according to the GCP regulations.
7. Allocation Of Responsibilities
7.1. The clinical affairs manager is responsible for the conduct and documentation of clinical
studies at [company].
7.2. The Clinical Research Associate (CRA) is responsible for monitoring the studies and
ensuring that they are conducted according to the protocol, SOP’s and GCP principles, as
applicable.
7.3. The QA manager is responsible for assuring full traceability on the study and for auditing
the site(s), as applicable.
7.4. The PI is responsible for the conduction of the study at the site according to the protocol,
SOP’s and GCP principles, as applicable.
8. Appendices
Appendix 1: Protocol - table of contents (as appropriate)
- Signature page
- Protocol Synopsis
- Introduction
- Device description
- Study objectives
- Study design (contraindications, study duration, inclusion/exclusion criteria, patient
enrollment, patient identification, baseline variables, study procedures)
- Ethics
- Adverse events
- Risk to benefit analysis
- Investigation administration
- CRF handling and data management (including statistical consideration)
QP-02-08 Page 13 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
Appendix 2: Investigator’s brochure – table of contents (as appropriate)
- Device description and function
- Processing information
- Risk analysis
- Bench testing
- Biocompatibility
- Animal studies
- Previous clinical studies (if applicable)
- Literature survey
Appendix 3: Informed consent – table of contents
- Purpose of the study
- Description of the research
- Compensation / reimbursements
- Insurance
- Potential risks and discomforts
- Potential benefits
- Alternatives to participation
- Confidentiality
- Voluntary participation
- Termination of participation
- Contact persons
Appendix 4: Items to be included in the Ethics Committee submission file (as
appropriate)
- Protocol / amendments
- Case Report Forms (CRF’s) – may be submitted as a draft
- Informed consent form(s) + translations
- Any other written information to be provided to patients
- Investigator’s brochure
- Investigator’s current CV
QP-02-08 Page 14 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
- Instructions For Use
Appendix 5: List of initial essential documents to be kept in regulatory binder (as
appropriate)
Before the clinical phase of the trial commences:
- Investigator’s brochure
- Signed protocol and amendments, if any
- Sample Case Report Forms (CRF)
- Informed consent form (including all applicable translations)
- Any other written information given to trial subject.
- Signed financial agreement of the trial
- Insurance statement (where required)
- Signed agreements between involved parties
- Approval of IRB/EC
- IRB/EC composition
- CV of investigator and sub-investigator
- Certification of medical/laboratory tests – as applicable
- Sample of labels attached to the investigational product
- Instructions for handling of investigational product and trial-related materials
- Shipping records – as applicable
- Site personnel identification list
- Site initiation monitoring report
During the clinical conduct of the trial
- Investigator’s brochure updates
- Amendments to the protocols, CRF’s, informed consent
- Approvals of IRB/EC to the amendments submitted
- Monitoring visit reports
- Relevant communications other than site visits (letters, meeting notes, regular
authorities…)
QP-02-08 Page 15 of 16
Proprietary and Confidential
document.docDocument: ProcedureDate: Jul 27, 2009Revision: XX
- Signed, dated and completed CRF’s. Note – the original CRF should be kept at the
sponsor’s headquarters and a copy of the CRF should be kept at the site file. If the CRF or
part of it is considered source data, a copy should be kept at the patient medical file.
- Documented adverse events reporting
- Subject enrollment list
- Subject identification code list (to be kept only at site)
- Investigational product accountability – as applicable
- Signature sheet
After completion or termination of the trial
- Documentation of investigational product return – as applicable
- Audit report, as applicable
- Site close out visit monitoring report
- Final report by investigator to IRB/EC and to the authorities, as applicable
- Clinical study report
QP-02-08 Page 16 of 16
Proprietary and Confidential